Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from AstraZeneca ( (AZN) ).
On August 22, 2025, The Capital Group Companies, Inc. increased its voting rights in AstraZeneca PLC to 5.009701%, surpassing the previous threshold of 4.997854%. This change, notified on August 25, 2025, indicates a strategic move by The Capital Group, potentially impacting AstraZeneca’s shareholder dynamics and market perception.
The most recent analyst rating on (AZN) stock is a Buy with a $84.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the AZN Stock Forecast page.
Spark’s Take on AZN Stock
According to Spark, TipRanks’ AI Analyst, AZN is a Outperform.
AstraZeneca’s strong financial performance and positive earnings call are the most significant factors driving the score. Technical analysis shows bullish momentum, though caution is advised due to overbought signals. The valuation suggests the stock may be overvalued, which slightly tempers the overall score.
To see Spark’s full report on AZN stock, click here.
More about AstraZeneca
AstraZeneca PLC is a UK-based pharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in areas such as oncology, cardiovascular, renal, metabolism, and respiratory.
Average Trading Volume: 4,484,077
Technical Sentiment Signal: Strong Buy
Current Market Cap: $250B
For an in-depth examination of AZN stock, go to TipRanks’ Overview page.